|
Anti-CD32B Mab
CD32B is expressed on B-cells, monocytes, macrophages, dendritic cells, basophils, and mast cells. When triggered, it delivers an inhibitory signal that contrasts those induced by activating receptors. The unique combination of cell type specific expression and inhibitory signal sensor suggests that CD32B is a valuable therapeutic target for multiple diseases. CD32B is over expressed in certain cancers, hence representing a target for cancer therapy. Therapeutic antibodies that block Fc engagement of CD32B may improve the efficacy of other cancer Mabs when co-administered. MacroGenics also believes that autoimmune and inflammatory diseases that are mediated by CD32B-expressing immune cells can be effectively treated.
|
